Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Latest News about Tiziana Life Sciences

Recent news which mentions Tiziana Life Sciences

Tiziana Expects To Start Enrolling Patients In Its Phase 2 Clinical Trial To Treat Secondary Progressive Multiple Sclerosis (SPMS) Using Its Novel Intranasal Monoclonal Antibody Foralumab
Tickers TLSA
Tags News Penny Stocks Benzinga
From Benzinga
Tiziana To Announce Six-Month Human Safety And Biomarker Data At The ECTRIMS Annual Congress, Following-Up From Positive Outcomes Data Presented In June
Tickers TLSA
Tags News Biotech Penny Stocks
From Benzinga
Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update
Tickers RHHBY SNY TLSA
Tags SNY Biotech Tiziana Life Sciences
From Benzinga
Tiziana Life Sciences Prepares To Advance Lead Intranasal Foralumab Program In First-Of-Its-Kind Phase 2a Clinical Trial for Non-Active SPMS Patients
Tickers TLSA
Tags Market News TLSA General
From Benzinga
Tiziana Reveals Alzheimer's Research Milestone With PNAS Journal After FDA IND Green Light
Tickers TLSA
Tags TLSA General Biotech
From Benzinga
Tiziana's Intranasal Foralumab For Alzheimer's Treatment Gets FDA Nod For Phase 2 Trials Under Brigham And Women's Hospital Supervision
Tickers TLSA
Tags News Biotech Benzinga
From Benzinga
As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab?
Tickers BAYRY SNY TLSA
Tags BAYRY Partner Content Market News
From Benzinga
Tiziana (NASDAQ: TLSA) Continues The Fight Against Multiple Sclerosis, Will Announce 6-Month Results For Its Novel Treatment Soon
Tickers SNY TLSA
Tags General TLSA Partner Content
From Benzinga
Neuroinflammation A Key Indicator For Alzheimer's, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
Tags General Partner Content Market News
From Benzinga
Phase 1 Results Are "Extraordinary," Says Chairman Of Scientific Advisory Board As Biomedical Company Preps Phase 2 Trial For MS Treatment
Tickers BAYRY SNY TSLA
Tags TSLA SNY News
From Benzinga
Publications And Positive Data From Multiple Trials: Six Months In Review For Tiziana Life Sciences (NASDAQ: TLSA)
Tickers SNY TLSA
Tags General TLSA Partner Content
From Benzinga
Tiziana Life Sciences (NASDAQ: TLSA) Announces Positive Data In Its Secondary-Progressive Multiple Sclerosis Trial, What Could This Mean For The Company?
Tickers PRVB SNY TLSA
Tags General TLSA Partner Content
From Benzinga
Tiziana's Foralumab Shown To Reduce Microglial Activation In MS Patients; Phase 2a Trial To Begin In Q3 2023
Tickers TLSA
Tags Market News TLSA General
From Benzinga
Tiziana Life Sciences To Submit Alzheimer's IND In Q2 2023, Seeks $3 Million From An Alzheimer's Foundation To Support Phase 2a Trial
Tickers TLSA
Tags General TLSA Market News
From Benzinga
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
Tickers EWTX IPHA PRVB SGEN
Tags Benzinga Biotech PRVB
From Benzinga
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise
Tickers PRVB SNY TLSA
Tags Market News Partner Content TLSA
From Benzinga
Tiziana Receives Sign-Off From The FDA To Proceed With Phase 2 Clinical Trial In Patients With Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
Tickers TLSA
Tags Market News General TLSA
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.